Tarloxotinib demonstrated preclinical efficacy in EGFR exon 20, HER2-mutant NSCLC, HER2-amplified NSCLC, and other oncogenic alterations in the ERBB gene family (such as NRG1 fusions).65 The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.